Adapting the coping in deliberation (CODE) framework: A multi-method approach in the context of familial ovarian cancer risk management

2014 ◽  
Vol 97 (2) ◽  
pp. 200-210 ◽  
Author(s):  
Jana Witt ◽  
Glyn Elwyn ◽  
Fiona Wood ◽  
Mark T. Rogers ◽  
Usha Menon ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Management ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
Familial Ovarian Cancer ◽  
Multi Method Approach ◽  
Method Approach ◽  
Cancer Risk Management

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome

2012 ◽  
Vol 11 (3) ◽  
pp. 473-482 ◽  
Author(s):  
Pascale This ◽  
Anne de la Rochefordière ◽  
Alexia Savignoni ◽  
Marie Christine Falcou ◽  
Anne Tardivon ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Management ◽  
Cancer Risk ◽  
Germline Mutation ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
French Cohort ◽  
Cancer Risk Management

scholarly journals Early experience in a breast and ovarian cancer risk management clinic in Malaysia

2012 ◽  
Vol 10 (Suppl 2) ◽  
pp. A58
Author(s):  
NA Taib ◽  
YL Woo ◽  
SY Yoon ◽  
R Kartini ◽  
MK Thong ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Management ◽  
Cancer Risk ◽  
Early Experience ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Cancer Risk Management

scholarly journals Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families

2012 ◽  
Vol 7 ◽  
pp. BMI.S10815 ◽  
Author(s):  
Ludmila Kaplun ◽  
Aviva Levine Fridman ◽  
Wei Chen ◽  
Nancy K. Levin ◽  
Sidra Ahsan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Allelic Variation ◽  
High Risk Population ◽  
Ovarian Cancer Risk ◽  
Familial Ovarian Cancer ◽  
Cell Growth And Differentiation ◽  
Brca1 Brca2 ◽  
High Risk Families

A substantial fraction of familial ovarian cancer cases cannot be attributed to specific genetic factors. The discovery of additional susceptibility genes will permit a more accurate assessment of hereditary cancer risk and allow for monitoring of predisposed women in order to intervene at the earliest possible stage. We focused on a population with elevated familial breast and ovarian cancer risk. In this study, we identified a SNP rs926103 whose minor allele is associated with predisposition to ovarian but not breast cancer in a Caucasian high-risk population without BRCA1/ BRCA2 mutations. We have found that the allelic variation of rs926103, which alters amino acid 52 of the encoded protein SH2D2A/TSAd, results in differences in the activity of this protein involved in multiple signal transduction pathways, including regulation of immune response, tumor vascularization, cell growth, and differentiation. Our observation provides a novel candidate genetic biomarker of elevated ovarian cancer risk in members of high-risk families without BRCA1/2 mutations, as well as a potential therapeutic target, TSAd.

Individualized Survival Curves Improve Satisfaction With Cancer Risk Management Decisions in Women With BRCA1/2 Mutations

2005 ◽  
Vol 23 (36) ◽  
pp. 9319-9328 ◽  
Author(s):  
Katrina Armstrong ◽  
Barbara Weber ◽  
Peter A. Ubel ◽  
Nikki Peters ◽  
John Holmes ◽  
...  
Keyword(s):  
Risk Management ◽  
Cancer Risk ◽  
Management Strategies ◽  
Ovarian Cancer Risk ◽  
Management Decisions ◽  
Management Options ◽  
Alternative Management ◽  
Decision Satisfaction ◽  
Cancer Risk Management

Purpose Women with BRCA1/2 mutations are faced with complex decisions about breast and ovarian cancer risk management. This study was conducted to determine the effect of a tailored decision support system (DSS) that provides individualized survival and cancer incidence curves specific to expected outcomes of alternative management strategies. Patients and Methods This was a double-blind, randomized controlled trial of 32 women with BRCA1/2 mutations. Primary outcome measures were decision satisfaction, cancer anxiety, perceptions of cancer risk given alternative management strategies, and management decisions. Results Twenty-seven women completed a 6-week follow-up. Women in the intervention arm (n = 13) reported significantly higher decision satisfaction at follow-up than women in the control arm (n = 14; adjusted mean difference, 9.7; P < .0005). The effect of the DSS was greater among women with low cancer anxiety at baseline than women with high cancer anxiety at baseline (P = .01 for interaction). However, the DSS did not significantly alter cancer anxiety at follow-up, perceptions of cancer risk given alternative management strategies, or management decisions. Conclusion The presentation of individualized survival and incidence curves for alternative management options improves satisfaction about cancer risk management decisions among women with BRCA1/2 mutations without increasing anxiety or changing management decisions. The benefit of the DSS is greatest among women with relatively low cancer-related anxiety at baseline.

Association of the ARLTS1 Variants With Familial Ovarian Cancer Risk in China

2009 ◽  
Vol 19 (4) ◽  
pp. 585-590 ◽  
Author(s):  
Xiao-Yun Yang ◽  
Hai Yu ◽  
Ming-Rong Xi ◽  
Kai-Xuan Yang ◽  
Xiao-Ling Pan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
Familial Ovarian Cancer

Ovarian Cancer Risk And Prevention

2002 ◽  
Author(s):  
Suzanne M. Miller ◽  
Carolyn Y. Fang ◽  
Karen Hurley
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Ovarian Cancer Risk
Sign in / Sign up

Export Citation Format

Share Document